Phase Ib dose escalation study of oral quisinostat, a histone deacetylase inhibitor, in combination with bortezomib and dexamethasone for patients with relapsed multiple myeloma

被引：0
|
作者：
Leleu, Xavier
Touzeau, Cyrille
Benboubker, Lotfi
Facon, Thierry
Delain, Martine
Fourneau, Nele
Phelps, Charles
Forslund, Ann
Hellemans, Peter
Smit, Johan
Badamo-Dotzis, Julie
Moreau, Philippe
机构：
[1] Hop Claude Huriez, Serv Malad Sang, Lille, France
[2] CHU Nantes, Hop Hotel Dieu, Serv Hematol, F-44035 Nantes 01, France
[3] Hop Bretonneau, Ctr Hosp Univ Tours, Tours, France
[4] Janssen Res & Dev LLC, Beerse, Belgium
[5] Janssen Res & Dev LLC, Raritan, NJ USA
[6] Janssen Res & Dev, Div Janssen Cilag, Providing Serv, Issy Les Moulineaux, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8530
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma
    San-Miguel, Jesus F.
    Richardson, Paul G.
    Guenther, Andreas
    Sezer, Orhan
    Siegel, David
    Blade, Joan
    LeBlanc, Richard
    Sutherland, Heather
    Sopala, Monika
    Mishra, Kaushal K.
    Mu, Song
    Bourquelot, Priscille M.
    Victoria Mateos, Maria
    Anderson, Kenneth C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) : 3696 - +
  • [22] Dose-escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma
    Iida, Shinsuke
    Ogiya, Daisuke
    Abe, Yasunobu
    Taniwaki, Masafumi
    Asou, Hiroya
    Maeda, Kaijiro
    Uenaka, Kazunori
    Nagaoka, Soshi
    Ishiki, Tsuyoshi
    Conti, Ilaria
    Tobinai, Kensei
    CANCER SCIENCE, 2016, 107 (09) : 1281 - 1289
  • [23] A PHASE IB STUDY OF THE AKT INHIBITOR AFURESERTIB IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: FINAL RESULTS WITH LONG TERM FOLLOW-UP
    Trudel, S.
    Spencer, A.
    Sutherland, H.
    O'Dwyer, M.
    Huang, S. Y.
    Stewart, A. K.
    Chari, A.
    Rosenzwieg, M.
    Nooka, A.
    Rosenbaum, C.
    Hofmeister, Cc
    Callander, N.
    Bengoudifa, B. R.
    Gadbaw, B.
    Reyes, M.
    Su, F.
    Voorhees, P.
    HAEMATOLOGICA, 2016, 101 : 82 - 82
  • [24] Bortezomib in combination with dexamethasone for relapsed multiple myeloma.
    Kropff, MH
    Bisping, G
    Wenning, D
    Berdel, WE
    Kienast, J
    BLOOD, 2004, 104 (11) : 313B - 313B
  • [25] A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma
    Rosenthal, Allison
    Kumar, Shaji
    Hofmeister, Craig
    Laubach, Jacob
    Vij, Ravi
    Dueck, Amylou
    Gano, Katherine
    Stewart, A. Keith
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (02) : 323 - 325
  • [26] Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
    Moreau, Philippe
    Chanan-Khan, Asher Alban Akmal
    Roberts, Andrew Warwick
    Agarwal, Amit
    Facon, Thierry
    Kumar, Shaji
    Touzeau, Cyrille
    Diehl, Susan
    Cordero, Jaclyn
    Ross, Jeremy A.
    Munasinghe, Wijith
    Zhu, Ming
    Salem, Ahmed H.
    Leverson, Joel
    Maciag, Paulo Cesar
    Verdugo, Maria E.
    Harrison, Simon J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma
    Kropff, Martin
    Bisping, Guido
    Schuck, Elke
    Liebisch, Peter
    Lang, Nicola
    Hentrich, Markus
    Dechow, Tobias
    Kroeger, Nicolaus
    Salwender, Hans
    Metzner, Bernd
    Sezer, Orhan
    Engelhardt, Monika
    Wolf, Hans-Heinrich
    Einsele, Hermann
    Volpert, Sarah
    Heinecke, Achim
    Berdel, Wolfgang E.
    Kienast, Joachim
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (03) : 330 - 337
  • [28] PANORAMA 2: A PHASE II STUDY OF PANOBINOSTAT IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED AND BORTEZOMIB-REFRACTORY MULTIPLE MYELOMA
    Richardson, P.
    Alsina, M.
    Weber, D.
    Coutre, S.
    Lonial, S.
    Gasparetto, C.
    Warsi, G.
    Ondovik, M.
    Mukhopadhyay, S.
    Paley, C.
    Schlossman, R.
    HAEMATOLOGICA, 2012, 97 : 338 - 338
  • [29] A Phase IB, Multicenter, Open-Label, Dose-Escalation Study of Oral Panobinostat (LBH589) and IV Bortezomib in Patients with Relapsed Multiple Myeloma.
    Siegel, David
    Sezer, Orhan
    Miguel, Jesus F. San
    Mateos, Maria-Victoria
    Prosser, Ian
    Cavo, Michele
    Jalaluddin, Muhammad
    Hazell, Katharine
    Bourquelot, Priscille M.
    Anderson, Kenneth C.
    BLOOD, 2008, 112 (11) : 960 - 961
  • [30] A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Campagnaro, Erica L.
    Lipe, Brea C.
    Nadeem, Omar
    Friedman, Robb S.
    Cole, Craig E.
    O'Donnell, Elizabeth K.
    Bianchi, Giada
    Branagan, Andrew R.
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra A.
    Mann, Mason L.
    Lohr, Jens G.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    BLOOD, 2019, 134
12345